BioVaxys presented results from the investigator-initiated PESCO trial of maveropepimut-S (MVP-S) combined with pembrolizumab and low-dose cyclophosphamide in recurrent epithelial ovarian cancer. MVP-S is a DPX-based vaccine built from five survivin-derived peptides plus a T-helper peptide and an innate immune stimulant, designed to drive a cytotoxic T-cell response against survivin, an antigen highly expressed in ovarian tumors but nearly absent in normal tissue.
BioVaxys presented additional validation data on May 1 supporting its MVP-S DPX-formulated five-peptide survivin vaccine in combination with checkpoint inhibitor pembrolizumab and low-dose cyclophosphamide in recurrent epithelial ovarian cancer. The new data extends the immune-response readout from the PESCO Phase 1B/2 program and reinforces the clinical case heading into the company's accepted ASCO 2026 abstract presentation (May 29–June 6, Chicago). MVP-S sits alongside Bicycle Therapeutics' Duravelo-2, BriaCell's Bria-IMT, Greenwich's GP2, Immutep's eftilagimod alfa, and Pfizer's 40+ oncology abstracts on the ASCO 2026 peptide-and-immuno-oncology slate.
BioVaxys announced April 27 that the abstract from the investigator-initiated PESCO trial — an open-label, non-randomized Phase 1B/2 study evaluating the company's MVP-S (maveropepimut-S) DPX-formulated peptide vaccine in combination with pembrolizumab and cyclophosphamide in recurrent epithelial ovarian cancer — has been accepted for presentation at the 2026 ASCO Annual Meeting in Chicago (May 29–June 6). MVP-S is a five-peptide survivin-targeted formulation that pairs the peptides with a T-helper sequence and an innate-immune stimulant; the program tests whether the cytotoxic T-cell response can be combined effectively with checkpoint blockade in platinum-resistant disease.